Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an ...
The following slide deck was published by Constellation Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Constellation Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Constellation Pharmaceuticals (NASDAQ: CNST) Q1 2021 Earnings Call May 10, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Constellation Pharmaceuticals (CNST) Q1 2021 Earnings Call Tr...
Constellation Pharmaceuticals, Inc. (CNST) Q1 2021 Results Conference Call May 10, 2021 08:00 AM ET Company Participants Kia Khaleghpour - VP, IR and Communications Jigar Raythatha - CEO Dr. Jeff Humphrey - Chief Medical Officer Emma Reeve - CFO Dr. Patrick Trojer - Chief Scientific Officer C...
Constellation Pharmaceuticals (CNST): Q1 GAAP EPS of -$0.84 misses by $0.05.Cash, cash equivalents, and marketable securities of $382.1M.Constellation expects that its current cash, cash equivalents, and marketable securities will fund operations into mid-2023.Press Release ...
Dosing underway in the Phase 3 MANIFEST-2 clinical trial Recommended Phase 2 dose determined for CPI-0209 and first patient dosed in the Phase 2 expansion cohorts Upcoming data presentation at ASCO supports the best-in-class target engagement potential of CPI-0209 ...
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its firs...
Image source: The Motley Fool. Constellation Pharmaceuticals (NASDAQ: CNST) Q4 2020 Earnings Call Feb 24, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Constellation Pharmaceuticals (CNST) Q4 2020 Earnings Call Tr...
Constellation Pharmaceuticals ([[CNST]] -26.0%) has dropped more than a quarter in value today after announcing Q4 2020 earnings results where it failed to meet the consensus estimates for the quarter.Compared to a ~42.7% YoY growth in 2019, the net loss for 2020 has jumped ~47.7% Y...
Constellation Pharmaceuticals, Inc. (CNST) Q4 2020 Earnings Conference Call February 24, 2021 08:00 AM ET Company Participants Kia Khaleghpour - Vice President, Investor Relations & Communications Jigar Raythatha - President & Chief Executive Officer Brendan Delaney - Chief Commercial...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...